What Is Pulsed Electromagnetic Field Therapy?

Pulsed electromagnetic field therapy, usually shortened to PEMF, is a category of treatment that uses brief electromagnetic pulses to influence cellular activity. Pulsed shortwave therapy (PSWT) is a specific form of PEMF that uses a defined frequency range and is the basis of the FDA cleared wearable devices used for musculoskeletal pain.

The simple version

A PEMF device produces a low intensity electromagnetic field that pulses on and off at a defined rate. The pulses pass through skin and tissue without producing heat, which is what makes them safe for extended wear. Inside cells, the pulses interact with ion channels and influence the timing of cellular signaling. That signaling is part of how the body manages inflammation, pain, and tissue repair.

What the FDA has cleared

The FDA has cleared specific PEMF and PSWT devices for specific indications. The most established cleared use is musculoskeletal pain and edema. PSWT wearables are cleared for that use and are the basis of the PAINKILLER product. Other PEMF devices are cleared for additional indications, including bone healing in certain settings. The cleared use is the use that the device should be described as, and the part of the broader market that stretches the language past the clearance creates confusion that hurts the category.

What the evidence says

The peer reviewed evidence on PSWT for musculoskeletal pain is meaningful. Randomized trials in knee osteoarthritis and cervical osteoarthritis have shown clinically relevant pain reduction. Multi center observational studies have shown the same pattern in real world deployment. The evidence base is not infinite, no clinical evidence base ever is, but it is enough to support both the FDA clearance and the routine clinical use.

How it is used

The wearable form factor is the part that has changed the practical use of the category. A modern PSWT device can be worn under clothing for hours at a time. The patient sets it up in the morning and goes about the day. There is no clinic visit required for routine use. The dose is duration driven, which is part of why the wearable form factor matters so much.

What to expect

Patients using PSWT for chronic musculoskeletal pain typically describe a steady accumulation of benefit over weeks rather than a dramatic week one change. Sleep, morning stiffness, and routine activity tend to be the most consistent improvements. The therapy fits into a multimodal plan rather than replacing other components.

How a session feels

A pulsed shortwave session feels like nothing in the conventional sense. There is no shock, no warming sensation, no buzz, no tingling. The device sits against the skin or under clothing and the field is delivered without the patient having to do anything. A typical wearable session runs continuously while the patient is in their normal day. The patient is not asked to be still, to interrupt their routine, or to focus on the therapy. That tactile invisibility is part of why duration based wearable PSWT produces a different clinical experience from older clinic anchored devices.

What the mechanism literature actually says

The mechanism literature on pulsed shortwave therapy describes its influence on ion channel timing, calcium signaling, nitric oxide production, and inflammatory mediator release. None of those pathways is a marketing simplification. They are the standard cellular pathways that pharmacology also targets, reached through a different physical mechanism. The literature is careful to distinguish thermal from non thermal effects of electromagnetic exposure. Modern PSWT is a non thermal modality, which is part of why the safety profile is favorable and why the duration of use can be measured in hours per day rather than minutes per week.

What patients should ask their clinician

Patients considering pulsed shortwave therapy should ask the same questions they would ask about any new option. Is this appropriate for my condition. Are there any contraindications I should know about, especially around implants. How long should I expect to use it before I see a meaningful change. How will we measure whether it is working. What does the rest of the plan look like. A clinician who is familiar with the FDA cleared device can answer each of those questions with reference to the agency cleared use and to the relevant literature. A platform that supports the device, like the Electrome platform behind PAINKILLER, can also surface the answers in patient facing language.

What clinicians should know

Clinicians evaluating PSWT for chronic pain should review the FDA clearance, the peer reviewed mechanism literature, and the clinical observation studies in musculoskeletal pain. They should understand the dose curve. They should be familiar with the standard precautions around implanted electronic devices. They should know that adherence is the largest single predictor of outcome, which is why a wearable platform with usage capture matters more than a higher peak intensity device used inconsistently. The clinician's role in pulsed shortwave therapy is the same as in any other component of a chronic pain plan. Set expectations honestly, integrate the input with the rest of the plan, and watch the longitudinal response.

What is next for the category

Pulsed electromagnetic field therapy is one of the most studied bioelectric modalities, and the next several years are likely to add more rigorous head to head comparisons against other non opioid options, more granular sub population data on which patients respond best, and more specialty society guidance on where the modality fits in standard care. The platforms that capture longitudinal data well will be the ones that contribute most to that body of evidence, and the patients are the constituency whose outcomes will determine how the category continues to grow.